Antiphospholipid antibodies in patients with antiphospholipid syndrome
Biochemia medica · 2024
DOI: 10.11613/bm.2024.020504 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemia medica, 2024. Verfasst von Slavica Dodig und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biochemistry and Hematology, Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia. Hauptthemen laut MEDLINE: Antiphospholipid Syndrome, Antibodies, Antiphospholipid. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Graphical abstract Highlights • Antiphospholipid syndrome is a rare systemic autoimmune disease characterized by recurrent pregnancy morbidity or thrombosis in combination with the persistent presence of antiphospholipid antibodies in plasma/serum • Specialists in laboratory medicine should take responsibility for the entire analytical process, so that possible interferences are minimized, and physicians obtain reliable results of the patient’s laboratory findings in a timely manner • Due to possible problems in performing tests on aPLs for a more reliable (optimal) interpretation of laboratory findings, a close cooperation between laboratory specialists and clinical specialists is needed Antiphospholipid syndrome (APS) is a rare systemic autoimmune disease characterized by recurrent pregnancy morbidity or thrombosis in combination with the persistent presence of antiphospholipid antibodies (aPLs) in plasma/serum. Antiphospholipid antibodies are a heterogeneous, overlapping group of autoantibodies, of which anti-β2-glycoprotein I (aβ2GPI), anticardiolipin (aCL) antibodies and antibodies that prolong plasma clotting time in tests in vitro known as lupus anticoagulant (LAC) are included in the laboratory criteria for the diagnosis of APS. The presence of LAC antibodies in plasma is indirectly determined by measuring the length of coagulation in two tests - activated partial thromboplastin time (aPTT) and diluted Russell’s viper venom time (dRVVT). The concentration of aβ2GPI and aCL (immunglobulin G (IgG) and immunoglobulin M (IgM) isotypes) in serum is directly determined by solid-phase immunoassays, either by enzyme-linked immunosorbent assay (ELISA), fluoroimmunoassay (FIA), immunochemiluminescence (CLIA) or multiplex flow immunoassay (MFIA). For patient safety, it is extremely important to control all three phases of laboratory testing, i.e. preanalytical, analytical and postanalytical phase. Specialists in laboratory medicine must be aware of interferences in all three phases of laboratory testing, in order to minimize these interferences. The aim of this review was to show the current pathophysiological aspects of APS, the importance of determining aPLs-a in plasma/serum, with an emphasis on possible interferences that should be taken into account when interpreting laboratory findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biochemistry and Hematology, Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia.
Zitieren
APA
Dodig, S., & Čepelak, I. (2024). Antiphospholipid antibodies in patients with antiphospholipid syndrome. Biochemia medica. https://doi.org/10.11613/bm.2024.020504
Vancouver
Dodig S, Čepelak I. Antiphospholipid antibodies in patients with antiphospholipid syndrome. Biochemia medica. 2024. doi:10.11613/bm.2024.020504
BibTeX
@article{Dodig2024,
author = {Dodig, Slavica and Čepelak, Ivana},
title = {Antiphospholipid antibodies in patients with antiphospholipid syndrome},
journal = {Biochemia medica},
year = {2024},
doi = {10.11613/bm.2024.020504}
}
EUVIMED